UBS Group
NUTX

UBS Group’s Nutex Health NUTX Stock Holding History

UBS Group’s Portfolio NUTX Stock Details NUTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.61M Buy
69,570
+14,545
+26% +$1.78M ﹤0.01% 3771
2025
Q4 		$9.06M Sell
55,025
-13,766
-20% -$1.83M ﹤0.01% 3395
2025
Q3 		$7.11M Buy
68,791
+23,316
+51% +$2.29M ﹤0.01% 3669
2025
Q2 		$5.66M Buy
45,475
+41,142
+950% +$5.31M ﹤0.01% 3749
2025
Q1 		$204K Sell
4,333
-1,489
-26% -$72.6K ﹤0.01% 6544
2024
Q4 		$184K Buy
5,822
+4,325
+289% +$123K ﹤0.01% 6496
2024
Q3 		$32.5K Buy
1,497
+66
+5% +$952 ﹤0.01% 7089
2024
Q2 		$8.51K Buy
1,431
+1,430
+143,000% +$10.3K ﹤0.01% 7798
2024
Q1 		$17 Buy
+1
New +$20 ﹤0.01% 9052
2023
Q4 		– Sell
-242
Closed -$7.37K – 9723
2023
Q3 		$7.37K Sell
242
-100
-29% -$4.82K ﹤0.01% 7239
2023
Q2 		$21.6K Sell
342
-441
-56% -$37.8K ﹤0.01% 6837
2023
Q1 		$119K Buy
783
+201
+35% +$40.7K ﹤0.01% 5788
2022
Q4 		$166K Buy
+582
New +$112K ﹤0.01% 5624
2022
Q3 		– Sell
-1
Closed -$424 – 10734
2022
Q2 		$0 Buy
+1
New +$1.18K ﹤0.01% 10726

Other funds holding NUTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PP
Pertento Partners London, United Kingdom $1.37B AUM 36.36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $605M AUM 26.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WC
Winmill & Co Rochester, New York $347M AUM 37.48% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

UBS Group's NUTX Position: Q1 2026 in Review

UBS Group increased its Nutex Health (NUTX) stake by 26% in Q1 2026, buying an estimated $1.78M and bringing the position to 69,570 shares worth $6.61M. The position accounts for ﹤0.01% of the portfolio, ranked #3771.

UBS Group first reported a position in NUTX in Q2 2022 and has held it in 14 quarters since. The position peaked at $9.06M in Q4 2025. 129 funds tracked by Wall St. Rank hold NUTX as of Q1 2026.

  • UBS Group held 69,570 shares of Nutex Health worth $6.61M as of Q1 2026.
  • UBS Group bought 14,545 Nutex Health shares in Q1 2026, an estimated $1.78M.
  • Nutex Health made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #3771 holding.
  • UBS Group first reported a position in Nutex Health in Q2 2022 and has held it in 14 quarters since.
  • UBS Group's Nutex Health position peaked at $9.06M in Q4 2025.
  • 129 funds tracked by Wall St. Rank held Nutex Health as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.